Literature DB >> 17043710

Spurious hypocalcemia after gadodiamide-enhanced magnetic resonance imaging: a case report and review of the literature.

Christopher D Moore, Robert C Newman, James G Caridi.   

Abstract

Gadolinium-enhanced magnetic resonance imaging is a diagnostic modality widely used in urologic practice. We report on a 54-year-old woman in whom a critically low serum calcium level was measured with standard colorimetric assay after gadodiamide-enhanced magnetic resonance imaging. The same phenomenon was noted in 2 other patients seen in our practice. Repeat serum calcium measurements performed several hours later were within normal limits. Commercially available gadolinium-based contrast agents might precipitate critically low serum calcium values when measured by standard colorimetric assay. Physician awareness of gadodiamide-induced spurious hypocalcemia might prevent unnecessary therapeutic interventions.

Entities:  

Year:  2006        PMID: 17043710      PMCID: PMC1578545     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  9 in total

Review 1.  Safety of magnetic resonance contrast media.

Authors:  V M Runge
Journal:  Top Magn Reson Imaging       Date:  2001-08

2.  More on pseudohypocalcemia and gadolinium-enhanced MRI.

Authors:  Martin R Prince; Peter L Choyke; Michael V Knopp
Journal:  N Engl J Med       Date:  2004-01-01       Impact factor: 91.245

3.  Interference of magnetic resonance imaging contrast agents with the serum calcium measurement technique using colorimetric reagents.

Authors:  J Lin; J M Idee; M Port; A Diai; C Berthommier; M Robert; I Raynal; L Devoldere; C Corot
Journal:  J Pharm Biomed Anal       Date:  1999-12       Impact factor: 3.935

4.  Spurious hypocalcemia after gadodiamide administration.

Authors:  Sandra F Williams; Shon E Meek; Thomas J Moraghan
Journal:  Mayo Clin Proc       Date:  2005-12       Impact factor: 7.616

5.  Renal tolerance of a neutral gadolinium chelate (gadobutrol) in patients with chronic renal failure: results of a randomized study.

Authors:  B Tombach; C Bremer; P Reimer; K Kisters; R M Schaefer; V Geens; W Heindel
Journal:  Radiology       Date:  2001-03       Impact factor: 11.105

6.  Spurious hypocalcemia after Omniscan- or OptiMARK-enhanced magnetic resonance imaging: an algorithm for minimizing a false-positive laboratory value.

Authors:  Jane Emerson; Gerald Kost
Journal:  Arch Pathol Lab Med       Date:  2004-10       Impact factor: 5.534

7.  Nephrotoxicity of high-dose gadolinium compared with iodinated contrast.

Authors:  M R Prince; C Arnoldus; J K Frisoli
Journal:  J Magn Reson Imaging       Date:  1996 Jan-Feb       Impact factor: 4.813

8.  Gadodiamide administration causes spurious hypocalcemia.

Authors:  Martin R Prince; Hale E Erel; Richard W Lent; Jon Blumenfeld; K Craig Kent; Harry L Bush; Yi Wang
Journal:  Radiology       Date:  2003-06       Impact factor: 11.105

9.  Interference of gadodiamide injection (OMNISCAN) on the colorimetric determination of serum calcium.

Authors:  P T Normann; A Frøysa; M Svaland
Journal:  Scand J Clin Lab Invest       Date:  1995-08       Impact factor: 1.713

  9 in total
  1 in total

Review 1.  A review of drug-induced hypocalcemia.

Authors:  George Liamis; Haralampos J Milionis; Moses Elisaf
Journal:  J Bone Miner Metab       Date:  2009       Impact factor: 2.626

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.